Israel Cancer Research Fund to Honor Alan Alda, Malcolm Hoenlein & Dr. Myron Schwartz at Tower of Hope Gala in NY - The Jewish Voice
70.9 F
New York
Tuesday, August 16, 2022

Israel Cancer Research Fund to Honor Alan Alda, Malcolm Hoenlein & Dr. Myron Schwartz at Tower of Hope Gala in NY

- Advertisement -

Related Articles


Must read

The Israel Cancer Research Fund (ICRF) Tower of Hope Gala will honor

Alan Alda, actor, writer, director; Malcolm Hoenlein, Executive Vice Chairman, CEO, Conference of Presidents of Major Jewish Organizations, and Dr. Myron Schwartz, Clinical Director of the Mount Sinai Liver Cancer Program at the Tower of Hope Gala, November 5 at the Edison Ballroom in New York City.  Benjamin Brafman, renowned criminal defense attorney, will serve as Master of Ceremonies. Ayla Schwartz, Young Elsa in Frozen, the Broadway musical, will perform, in addition to Cantor Laura Stein and Nikki Yannell.


Malcolm Hoenlein, Executive Vice Chairman, CEO, Conference of Presidents of Major Jewish Organizations is another meritorious honoree at the ICRF Tower of Hope gala in NY

“At the Tower of Hope gala, we will be honoring three truly towering figures in their chosen fields of endeavor—an advocate (Malcolm Hoenlein), a humanitarian (Alan Alda) and a healer (Dr. Myron Schwartz),each without peer, said Dr. Mark Israel, National Executive Director of ICRF.    “It is our honor to be able to thank them. I hope some small fraction of the many people they have helped and lifted up will join us to express their gratitude on this special occasion.”


Alan Alda, a seven-time Emmy Award and Global Award winner, played Hawkeye Pierce and wrote many of the episodes on the classic TV series M*A*S*H, and appeared in continuing roles in ER, the West Wing, 30 Rock and The Blacklist.  He has starred, written and directed many films, and was nominated for an Academy Award for his role in The Aviator.  On Broadway, he received Tony nominations for Glengarry Glen Ross, Jakes’ Women, and The Apple Tree.


His interest in science led to his hosting the award–winning PBS series Scientific American Frontiers for 11 years, for which he interviewed hundreds of scientists. Also on PBS, he hosted the miniseries The Human Spark, and Brains on Trial.  Alda is a Visiting Professor at Stony Brook University’s Alan Alda’s Center for Communicating Science which he helped found. The Center has 17 affiliate universities in the U.S. and Australia.  Most recently, it was announced that Alda will receive the lifetime achievement award from the Screen Actors Guild on January 27 in Los Angeles.


“Alan Alda is a singular talent, and rightfully so, one of the most universally beloved entertainers of the last 50 years, noted ICRF President Rob Densen. “But as impressive as is his IMDb, I believe his most significant and enduring societal contribution will prove to be his brilliant, far-sighted efforts to help broaden the public’s understanding of science and now, to enhance communications among medical practitioners, and in turn, between physicians and patients.”


Malcolm Hoenlein has served as CEO of the Conference of Presidents of Major Jewish Organizations, the central coordinating body on international and national concerns for 50 national Jewish organizations, since 1986.  He was the founding Executive Director of the Jewish Relations Council of Greater New York, and the founding Executive Director of the Greater New York Conference on Soviet Jewry.


As an “ambassador” for the Jewish people. Hoenlein has travelled across the globe meeting with top world leaders, heads of Jewish communities, business leaders and opinion makers. He has also served as an advisor to many national public officials and is frequently consulted on public policy issues. A recipient of numerous awards and tributes, Hoenlein received the highest civilian decoration from His Majesty, King Mohammad VI of Morocco and Jerusalem’s most coveted tribute, the Trustee of Jerusalem Award , from The Mayor of Jerusalem and the City Council .  He was also appointed by three American presidents as a U. S. delegate to the Organization for Security and Cooperation in Europe and participated in several Presidential delegations.


“Malcolm has been an articulate, forceful and tireless representative of the Jewish people, both here and abroad. For more than 30 years, wherever and whenever the welfare of Jews has required a passionate and   effective defense, Malcolm has been there,” said Densen.


– Dr. Myron Schwartz, Clinical Director of the Mount Sinai Liver Cancer Program will receive a much deserved honor at the ICRF Tower of Hope Gala which will take place on November 5 at the Edison Ballroom in New York City

Dr. Myron Schwartz joined the faculty of Mount Sinai in1987. He worked with Dr. Charles Miller to establish the Mount Sinai Liver Transplant Program in 1988, and since then has devoted his career to hepatobiliary surgery and transplantation. Over the years, he has served as Director of Pediatric and Adult Liver Transplantation, and more recently has focused on liver cancer as   Clinical Director of the Mount Sinai Liver Cancer Program.  Together with Research Director Dr. Joseph Llovet, Dr. Schwartz has led the collaborative effort that has placed Mount Sinai at the forefront world-wide in liver cancer and clinical translational research. He has published more than 300 papers in peer-reviewed journals, as well as 21 book chapters.


 “As the former director of the Comprehensive Cancer Center at Dartmouth, it is truly an honor for me to honor such a brilliant surgeon and compassionate healer who has helped to change the course of liver disease.  Dr. Schwartz’s efforts have saved hundreds of lives and, together with his colleagues, put Mount Sinai at the vanguard of liver cancer treatment and research. He is a dedicated physician and researcher in the highest and best tradition of ICRF, said Dr. Israel.”


The Israel Cancer Research Fund is the largest charitable organization outside of Israel solely devoted to supporting cancer research in Israel. Grants issued by ICRF have gone to hundreds of researchers (ICRF grantees include the first two Israelis to win the Nobel Prize in Chemistry, multiple winners of the coveted Israel Prize and other global scientific awards)  at two dozen leading research institutions, universities, and hospitals across Israel. The efforts of Israeli cancer researchers have resulted in significant cancer breakthroughs and in the development of breakthrough cancer drugs, including Doxil, Gleevec and Velcade. ICRF’s current collaborations with two major cancer research organizations, The Cancer Research Institute and City of Hope, demonstrate the global research community’s respect for ICRF.


For more information about the Tower of Hope Gala, please contact Kenneth Gabel, New York Director of Development, Tel. (212) 969 9800,




balance of natureDonate

Latest article

- Advertisement -
Skip to content